Literature DB >> 33496858

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.

Shuji Terai1, Amy Buchanan-Hughes2, Alvin Ng3, I-Heng Lee4, Ken Hasegawa5.   

Abstract

BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision (MDV) claims database, from January 2011 to March 2018. Demographics were described at index date and by calendar year; a "NASH" subpopulation included patients with ≥ 1 claim for NASH at any time. Prevalence of pre-specified comorbidities of interest and data-emergent top comorbidities were estimated. All-cause HCRU and costs were quantified by calendar year. Outcomes were compared between 2011 and 2017 using partially overlapping t tests.
RESULTS: 58,958 patients (mean age 61.6 years; 55.5% male) were included. 1139 patients (2%) were in the NASH subpopulation. At baseline, comorbid cardiovascular disease (69.4%), diabetes (62.1%) and hyperlipidaemia (54.4%) were most prevalent; comorbidity prevalence increased with age. Mean outpatient visits decreased from 9.36 per patient in 2011 to 7.80 in 2017; mean inpatient admissions increased (both p < 0.001 for 2011 vs 2017). Mean total all-cause healthcare costs ranged from ¥322,206 to ¥340,399 per patient per year between 2011 and 2017. Although total all-cause healthcare costs did not change significantly (p = 0.552), cost burden shifted from the outpatient to inpatient setting between 2011 and 2017. All-cause healthcare resource use/costs were generally higher for the NASH subgroup compared with the overall population.
CONCLUSIONS: There is a high burden of disease among Japanese NAFLD/NASH patients, including a high prevalence of comorbidities which generally increase with age. Accordingly, substantial all-cause HCRU and costs were incurred.

Entities:  

Keywords:  Cost; Database analysis; Japan; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Year:  2021        PMID: 33496858      PMCID: PMC7932941          DOI: 10.1007/s00535-021-01759-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  2 in total

Review 1.  Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.

Authors:  Ramesh Kumar; Shantam Mohan
Journal:  J Clin Transl Hepatol       Date:  2017-07-05

2.  Why, When and How to Adjust Your P Values?

Authors:  Mohieddin Jafari; Naser Ansari-Pour
Journal:  Cell J       Date:  2018-08-01       Impact factor: 2.479

  2 in total
  4 in total

Review 1.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

2.  Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.

Authors:  Teruki Miyake; Osamu Yoshida; Bunzo Matsuura; Shinya Furukawa; Masashi Hirooka; Masanori Abe; Yoshio Tokumoto; Yohei Koizumi; Takao Watanabe; Eiji Takeshita; Kotaro Sunago; Atsushi Yukimoto; Kyoko Watanabe; Masumi Miyazaki; Sayaka Kanzaki; Hironobu Nakaguchi; Mitsuhito Koizumu; Yasunori Yamamoto; Teru Kumagi; Yoichi Hiasa
Journal:  Diabetes Ther       Date:  2022-03-21       Impact factor: 3.595

Review 3.  Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease.

Authors:  Min Kyo Jeong; Byeong Hyun Min; Ye Rin Choi; Ji Ye Hyun; Hee Jin Park; Jung A Eom; Sung Min Won; Jin Ju Jeong; Ki Kwang Oh; Haripriya Gupta; Raja Ganesan; Satya Priya Sharma; Sang Jun Yoon; Mi Ran Choi; Dong Joon Kim; Ki Tae Suk
Journal:  Foods       Date:  2022-09-05

4.  A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice.

Authors:  Satoko Motegi; Atsunori Tsuchiya; Takahiro Iwasawa; Takeki Sato; Masaru Kumagai; Kazuki Natsui; Shunsuke Nojiri; Masahiro Ogawa; Suguru Takeuchi; Yosiki Sakai; Shigeru Miyagawa; Yoshiki Sawa; Shuji Terai
Journal:  Inflamm Regen       Date:  2022-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.